ALUPENT
LOE ApproachingNDAINHALATIONAEROSOL, METEREDPriority Review
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is a metered-dose aerosol inhalation therapy approved in 1973 by Boehringer Ingelheim as an NDA small-molecule product. The generic name and specific mechanism of action are not disclosed in available data, but the inhalation route and aerosol formulation suggest a respiratory indication. This is a legacy product approaching loss of exclusivity.
LOE Approaching
With LOE approaching and modest competitive pressure (30%), the brand team is likely in maintenance or defensive positioning mode with reduced commercial resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and approaching LOE, ALUPENT offers limited career growth potential. Roles on this product are primarily defensive and compliance-focused, making it a lower-priority assignment for ambitious professionals seeking expansion or launch experience.
Brand ManagerProduct Manager
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.